Results 21 to 30 of about 3,000 (187)

Global prevalence of resistance to rifampicin in Mycobacterium leprae: A meta-analysis

Journal of Global Antimicrobial Resistance, 2022
Objectives: As the only bactericidal drug in multidrug therapy is rifampicin, monitoring of antimicrobial resistance is important in leprosy patients. Therefore, we conducted a meta-analysis on the resistance of Mycobacterium leprae (M.
Chen Wang, Ziwei Wu, Haiqin Jiang, Ying Shi, Wenyue Zhang, Mengyan Zhang, Hongsheng Wang   +6 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone ST228, Spain

BMC Microbiology, 2010
Background Methicillin-resistant S. aureus (MRSA) has been endemic in Hospital Universitari de Bellvitge, Barcelona, since 1990. During the 1990-95 period the Iberian clone (ST-247; SCCmec-I) was dominant. Isolates of clonal complex 5 (ST-125; SCCmec-IV)
Liñares Josefina, Tubau Fe, Domínguez M Angeles, Mick Virginie, Pujol Miquel, Martín Rogelio   +5 more
doaj   +1 more source

Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosis.

PLoS ONE, 2013
IntroductionRapid tests for rifampicin resistance may be useful for identifying isolates at high risk of drug resistance, including multidrug-resistant TB (MDR-TB).
Matthew Arentz, Bess Sorensen, David J Horne, Judd L Walson   +3 more
doaj   +1 more source

Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study

Frontiers in Public Health, 2022
BackgroundFluoroquinolones (FQs) are the most important second-line anti-tuberculosis (anti-TB) drugs, primarily used for the treatment of multidrug- or rifampicin-resistant TB (MDR/RR-TB).
Yangyi Zhang, Yangyi Zhang, Yangyi Zhang, Yuan Jiang, Yuan Jiang, Chenlei Yu, Chenlei Yu, Jing Li, Jing Li, Xuhui Shen, Xuhui Shen, Qichao Pan, Qichao Pan, Xin Shen, Xin Shen   +14 more
doaj   +1 more source

Rifampicin Resistance Associated with rpoB Mutations in Neisseria gonorrhoeae Clinical Strains Isolated in Austria, 2016 to 2020

Microbiology Spectrum, 2022
Due to increasing rates of antimicrobial resistance (AMR) in Neisseria gonorrhoeae, alternative treatments should be considered. To assess rifampicin’s potential as a gonorrhea treatment, we used rpoB mutations to estimate rifampicin resistance in ...
Justine Schaeffer, Kathrin Lippert, Sonja Pleininger, Anna Stöger, Petra Hasenberger, Silke Stadlbauer, Florian Heger, Angelika Eigentler, Alexandra Geusau, Alexander Indra, Franz Allerberger, Werner Ruppitsch   +11 more
doaj   +1 more source

Inactivation of a New Potassium Channel Increases Rifampicin Resistance and Induces Collateral Sensitivity to Hydrophilic Antibiotics in Mycobacterium smegmatis

Antibiotics, 2022
Rifampicin is a critical first-line antibiotic for treating mycobacterial infections such as tuberculosis, one of the most serious infectious diseases worldwide.
Thi Thuy Do, Jerónimo Rodríguez-Beltran, Esmeralda Cebrián-Sastre, Alexandro Rodríguez-Rojas, Alfredo Castañeda-García, Jesús Blázquez   +5 more
doaj   +1 more source

Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.

PLoS ONE, 2020
BackgroundPakistan is among top five high burden countries for tuberculosis and drug resistant TB. Among rifampicin sensitive new pulmonary TB (PTB), prevalence of isoniazid resistance is 8.3% (95%CI: 7.0-10.7) and resistance to fluoroquinolone is higher
Sabira Tahseen, Faisal Masood Khanzada, Alamdar Hussain Rizvi, Mahmood Qadir, Aisha Ghazal, Aurangzaib Quadir Baloch, Tehmina Mustafa   +6 more
doaj   +1 more source

False rifampicin resistant results using Xpert MTB/RIF on urine samples in hospitalised HIV-infected patients

Southern African Journal of HIV Medicine, 2019
Background: A small proportion of false rifampicin resistant results have previously been reported using GeneXpert MTB/RIF version G4 on sputum samples; however, this has not been investigated for urine samples in HIV-associated tuberculosis (TB ...
Charlotte Schutz, Amy Ward, Rosie Burton, Mark P. Nicol, Liz Blumenthal, Graeme Meintjes, Andrew D. Kerkhoff   +6 more
doaj   +1 more source

Diagnosis of rifampicin-resistant tuberculosis: Discordant results by diagnostic methods

African Journal of Laboratory Medicine, 2018
The performance of the Xpert© MTB/RIF and MTBDRplus assays for the detection of rifampicin resistant Mycobacterium tuberculosis was compared to culture-based drug susceptibility testing in 30 specimens with rifampicin-resistant and rifampicin ...
Winnie Mwanza, Deborah Milimo, Maureen M. Chilufya, Nkatya Kasese, Maina C. Lengwe, Stembiso Munkondya, Petra de Haas, Helen Ayles, Monde Muyoyeta   +8 more
doaj   +1 more source